SCHEMBL2331866

SCHEMBL2331866

COc1ccccc1OC1CN(CC(C)O)CCN1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
HTR1A P08908 3/20 0.36
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
GNAI3 P08754 1/20 0.35
ATM Q13315 1/20 0.35
RECQL P46063 1/20 0.35
DRD2 P14416 1/20 0.35
HTR7 P34969 1/20 0.35
IGF1R P08069 1/20 0.34
ALOX15 P16050 1/20 0.34
FPR1 P21462 1/20 0.34
JAK2 O60674 1/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11619919 0.87 KMT2A (0.42) ALOX15MAPTPOLBALDH1A1MEN1
SCHEMBL6184734 0.82 GRIN1 (0.40) DRD2MAPTPOLBMEN1KMT2A
SCHEMBL6185585 0.81 TP53 (0.41) MAPT
SCHEMBL8349073 0.78 USP2 (0.41) CHRM2MAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL11620280 0.76 SMN1; SMN2 (0.36)
SCHEMBL6193609 0.68 CHRNB4 (0.40) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL5745430 0.68 CYP3A4 (0.41)
SCHEMBL6185503 0.68 L3MBTL1 (0.39) ALOX15MAPTALDH1A1MEN1KMT2A
SCHEMBL6186053 0.68 CYP3A4 (0.41)
SCHEMBL11626341 0.67 RECQL (0.68) HTR1ARECQLDRD2IGF1RALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356097-A2 HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Actavis Group PTC ehf. (IS) 2011-08-17 EP disclosed
WO-2010043976-A2 HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2010-04-22 WO disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed